OCT+CMR Combined Identify Underlying Cause in Majority of MINOCA Cases, No Sex Differences in Mechanisms: The HARP Trial
Key Points Myocardial infarction with no obstructive coronary arteries accounts for approximately 6% of all MI cases and up to 15% of women presenting with NSTEMI;... Read more.
Prehospital Heparin Improves Coronary Patency in STEMI Without Excess Bleeding: UFH-STEMI Trial
Key Points Unfractionated heparin is standard anticoagulation during primary PCI for STEMI, but optimal timing of administration has remained uncertain. The UFH-STEMI... Read more.
NT-proBNP-Based Screening Identifies Undiagnosed Heart Failure in Patients with Diabetes: The TARTAN-HF Trial
Key Points Heart failure affects patients with diabetes at disproportionately high rates, yet it frequently goes unrecognized until clinical decompensation occurs.... Read more.
Tirzepatide Reduces Cardiorenal Outcomes vs Dulaglutide in Patients with Diabetes and CV Disease: SURPASS-CVOT Post Hoc Analysis
Key Points Tirzepatide targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, producing greater weight loss and more favorable glycemic... Read more.
IVUS- guided PCI Reduces One-Year Target Vessel Failure vs Angiography -guided PCI in Complex Bifurcation PCI: DKCRUSH VIII Trial
Key Points Intravascular imaging has been increasingly recognized as a cornerstone of contemporary percutaneous coronary intervention, particularly for complex coronary... Read more.
IVUS-guided PCI was Not Associated with Lower Risk of Target-Vessel Failure vs Angiography-guided PCI alone in Complex High-Risk PCI: IVUS-CHIP Trial
Key Points Intravascular ultrasound guidance during percutaneous coronary intervention has been associated with improved stent optimization and reduced adverse events... Read more.
Asundexian Associated with an Impressive 26% Reduction in Recurrent Stroke Without Increased Bleeding. The OCEANIC-STROKE trial
Asundexian is a direct, potent small molecule inhibitor of Factor XIa (FXIa). Previously, in a randomized, placebo-controlled, double-blind, dose-finding trial of... Read more.
NOAC Monotherapy Non-Inferior to Combination Therapy for Net Adverse Clinical events in AF Patients Post–DES: ADAPT AF-DES Trial
Key Points The ADAPT AF-DES randomized trial compared NOAC monotherapy (apixaban or rivaroxaban) versus NOAC plus clopidogrel in atrial fibrillation (AF) patients... Read more.
Prasugrel Might be a Better Choice than Ticagrelor For DAPT after PCI for Patients with Diabetes and MVD: The TUXEDO-2 Trial
Key Points TUXEDO-2 directly compared ticagrelor vs prasugrel based DAPT in 1,800 patients with diabetes and multivessel coronary artery disease (MVD) undergoing... Read more.
Two Factor XI Antibodies For the Prevention of Post- operative VTE: Results from ROXI-VTE-I and ROXI-VTE-II Trials
Key Points: ROXI-VTE-I and ROXI-VTE-II evaluated two distinct factor XI monoclonal antibodies REGN9933A2 and REGN7508Cat, for prevention of venous thromboembolism... Read more.